Clinical Trials Logo

ALK-positive Advanced NSCLC clinical trials

View clinical trials related to ALK-positive Advanced NSCLC.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03535740 Active, not recruiting - Clinical trials for ALK-positive Advanced NSCLC

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

ALTA-2
Start date: January 31, 2019
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to determine the efficacy of brigatinib by confirmed objective response rate (ORR) by response evaluation criteria in solid tumors (Response Evaluation Criteria in Solid Tumors [RECIST]), in participants with ALK+ locally advanced or metastatic NSCLC whose disease has progressed on therapy with alectinib or ceritinib.